# Bluejay Diagnostics Meets Japan Manufacturing Milestone Ahead of Schedule

- URL: https://stocks.freetheai.org/news/bluejay-diagnostics-meets-japan-manufacturing-milestone-ahead-of-schedule-5d6027
- Published: 2026-10-13T10:30:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:BJDX](https://stocks.freetheai.org/symbols/NASDAQ-BJDX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Bluejay Diagnostics, Inc. (BJDX) has set up a Symphony cartridge manufacturing site at SanyoSeiko in Japan. The completion satisfies a key licensing milestone under its agreement with Toray well ahead of the October 23, 2026 deadline. The company is also adding manufacturing capacity in the United States through ALURIS to support future scale-up efforts.

Establishing dedicated production facilities in Japan and securing supplemental U.S. output helps secure supply readiness and reduce logistics risks. Because the investigational Symphony IL-6 system has not received clearance from the U.S. Food and Drug Administration, commercial revenue remains contingent on securing future regulatory authorization. Shares of Bluejay Diagnostics fell 3.85% to $0.7922 today.

Investors will be monitoring upcoming operational steps, including the readout from the pivotal SYMON-II trial. A successful 510(k) regulatory submission and subsequent clearance are key prerequisites for the company to move toward commercial distribution and revenue generation.

## Key points

- Bluejay Diagnostics, Inc. (BJDX) established a Symphony cartridge manufacturing site at SanyoSeiko in Japan.
- The achievement fulfills a licensing milestone under a Toray contract ahead of an October 23, 2026 deadline.
- The company secured additional U.S. production capacity through ALURIS to strengthen supply resilience.
- Symphony IL-6 remains investigational and requires FDA clearance before commercialization and revenue generation.

## Questions and answers

### What manufacturing milestone did Bluejay Diagnostics reach?

Bluejay Diagnostics established a Symphony cartridge manufacturing site at SanyoSeiko in Japan, meeting a Toray contract milestone ahead of the October 23, 2026 deadline.

### Is Bluejay Diagnostics' Symphony IL-6 cleared by the FDA?

No, Symphony IL-6 is an investigational product that has not yet received FDA clearance. Commercial revenue depends on future regulatory approval.

### How is Bluejay Diagnostics expanding its U.S. manufacturing capacity?

Bluejay Diagnostics is adding U.S. manufacturing capacity through ALURIS to build redundancy and support future production scaling.